Partial Leptin Reduction: An Emerging Weight Loss Paradigm
Mohammed K Hankir1, Florian Seyfried2
1Department of Experimental Surgery, University Hospital Wuerzburg, Wuerzburg 97080, Bavaria, Germany.
Abstract:
Leptin-based obesity pharmacotherapies were originally developed according to the lipostatic view that elevated circulating leptin levels promote a negative energy balance. A series of independent preclinical findings suggest, however, that a partial reduction in circulating leptin levels (either by immunoneutralization, a peripherally restricted CB1 receptor inverse agonist, or bariatric surgery) can paradoxically lead to weight loss.
Related Concept Videos
Regulation of Food Intake
Obesity
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Drug Dosing: Obese Patients
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion


